Larry D. Lynd

Professor Larry D. Lynd is a prominent researcher at the University of British Columbia's Faculty of Pharmaceutical Sciences, with additional appointments as a Scientist at the Centre for Health Evaluation and Outcome Sciences (CHEOS) at Providence Health Care Research Institute, Director of the Collaboration for Outcomes Research and Evaluation (CORE), Scholar at the Peter Wall Institute of Advanced Studies, and Associate of the UBC School of Population and Public Health.

Dr. Lynd completed his PhD in the Department of Health Care and Epidemiology at UBC and a post-doctoral fellowship in health economics at McMaster University. As a pharmacist (BSP) and epidemiologist, he has developed a distinguished career at the intersection of health outcomes research, epidemiology, and health economics, with a particular focus on the application of large administrative health datasets to inform practice and policy.

His research spans multiple high-impact areas including rare diseases, multiple sclerosis, respiratory disease, and genomic medicine. Dr. Lynd leads major research initiatives such as the CANadian PROactive Cohort study for People Living with MS, the GenCOUNSEL study evaluating whole genome sequencing for clinical genetic services, and the Early Health Technology Assessment platform for the Nanomedicines Innovation Network. His recent publications demonstrate a strong emphasis on health technology assessment, genomic medicine implementation, multiple sclerosis outcomes research, and addressing unmet needs in clinical genetic services.

Dr. Lynd's scientific contributions have been recognized through prestigious awards including the Dr. John McNeil Excellence in Health Research Mentorship Award (2022), Fellowship in the Canadian Academy of Health Sciences (2018), and the UBC Faculty of Pharmaceutical Sciences PharmD Teaching Award (2014-2015).

As a mentor, Dr. Lynd has supervised doctoral students including Tamara Mihic (PhD in Pharmaceutical Sciences) and Kennedy Borle (PhD in Interdisciplinary Studies). He has secured substantial research funding, with recent grants totaling over $5 million from organizations including the Canadian Institutes for Health Research, Genome Canada, MS Society of Canada, and Genome British Columbia.

Dr. Lynd actively contributes to health policy through leadership roles on committees including as chair of the Health Canada Special Advisory Committee on Non-Prescription Drugs, Special Advisory Committee to the Respiratory and Allergy Therapies Division of Health Canada, BC Ministry of Health Services Expensive Drugs for Rare Diseases Committee, and the BC PharmaNet Data Stewardship Committee.